MedTrace Logo

Low-dose Rituximab and High-dose Dexamethasone as First Line Treatment for ITP

NCT01107951 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2013-03-22

No results posted yet for this study

Summary

The purpose of this study is to determine the response rate and response duration with the combination of low-dose rituximab and high-dose dexamethasone in the treatment of adult immune thrombocytopenic purpura.

Conditions

  • Immune Thrombocytopenic Purpura

Interventions

DRUG

Rituximab and dexamethasone

Rituximab 100mg IV days 1,8,15,22. Dexamethasone 40mg PO days 1-4 (four days)

Sponsors & Collaborators

  • Hospital Universitario Dr. Jose E. Gonzalez

    lead OTHER

Principal Investigators

  • David Gomez-Almaguer, MD · Hospital Universitario

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2010-04-30
Completion
2013-01-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01107951 on ClinicalTrials.gov